Alberto F Sobrero

Alberto F Sobrero

UNVERIFIED PROFILE

Are you Alberto F Sobrero?   Register this Author

Register author
Alberto F Sobrero

Alberto F Sobrero

Publications by authors named "Alberto F Sobrero"

Are you Alberto F Sobrero?   Register this Author

19Publications

817Reads

12Profile Views

Maximising clinical benefit with adequate patient management beyond the second line in mCRC.

ESMO Open 2019 13;4(2):e000495. Epub 2019 May 13.

Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555611PMC
May 2019

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

N Engl J Med 2018 Mar;378(13):1177-1188

From the Divisions of Medical Oncology (A.G.) and Biomedical Statistics and Informatics (Q.S., J.P.M., L.A.R., D.J.S.), Mayo Clinic, Rochester, MN; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino-IST, Genoa (A.F. Sobrero), Ospedale Papa Giovanni XXIII, Bergamo (R.L.), and IRCCS Mario Negri Institute for Pharmacological Research, Milan (V.T.) - all in Italy; Karmanos Cancer Institute, Wayne State University, Detroit (A.F. Shields); National Cancer Center Hospital East, Chiba (T. Yoshino), Yokohama City University School of Medicine, Yokohama (T. Yamanaka), and the University of Tokyo, Tokyo (T.W.) - all in Japan; the Institute of Cancer Sciences, University of Glasgow, Glasgow (J.P.), the University of Oxford, Oxford (R.K.), Christie Hospital, Manchester (M.S.), and University Hospital Southampton, Southampton (T.I.) - all in the United Kingdom; Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University (J.T.), and Saint-Antoine Hospital and Sorbonne Universités, Pierre and Marie Curie University-Paris 6 (T.A.), Paris, and Methodology and Quality of Life Unit, INSERM Unité 1098, Besançon (D.V.) - all in France; the Department of Medical Oncology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion (J.S.), and Bioclinic Thessaloniki, Thessaloniki (I.B.) - both in Greece; Dana-Farber Cancer Institute, Boston (J.A.M.); and Duke Cancer Institute, Durham, NC (D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426127PMC
March 2018

Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors.

Clin Cancer Res 2015 Mar 17;21(5):1036-43. Epub 2014 Sep 17.

Medical Oncology and Epidemiology, IRCCS AOU San Martino IST, Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1505DOI Listing
March 2015

Current opinion on optimal treatment for colorectal cancer.

Expert Rev Anticancer Ther 2013 May;13(5):597-611

The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.13.37DOI Listing
May 2013

Second-line therapy for advanced colorectal cancer.

Gastrointest Cancer Res 2007 Mar;1(2):57-63

Department of Medical Oncology, Ospedale San Martino, Genova, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632873PMC
March 2007

Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.

J Clin Oncol 2004 Jan 9;22(1):4-6. Epub 2003 Dec 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.11.974DOI Listing
January 2004